Revenue: As of FY2026 Q2, the actual value is USD 83.22 M, beating the estimate of USD 80.48 M.

EPS: As of FY2026 Q2, the actual value is USD 0.28, beating the estimate of USD 0.24.

EBIT: As of FY2026 Q2, the actual value is USD 48.79 M.

Aurinia Pharmaceuticals Inc. reported financial results for the three and six months ended June 30, 2026.

Financial Results for the Three Months Ended June 30, 2026

• Total Revenue: Aurinia Pharmaceuticals Inc. generated $83.2 million in total revenue, marking a 19% increase from $70.0 million in the same period of 2025.
• Net Product Sales: Net product sales were $79.4 million, up 19% from $66.6 million in the prior year period.
• License, Collaboration and Royalty Revenue: License, collaboration, and royalty revenue increased by 12% to $3.8 million, from $3.4 million in the same period of 2025.
• Net Income: Net income for the period was $37.4 million, a 74% increase compared to $21.5 million in the same period of 2025.
• Income from Operations: Income from operations stood at $46,341 thousand.
• Total Operating Expenses: Total operating expenses were $36,879 thousand.
• Cash Flows from Operating Activities: Cash flows from operating activities increased by 19% to $52.5 million, up from $44.2 million in the same period of 2025.

Financial Results for the Six Months Ended June 30, 2026

• Total Revenue: Total revenue reached $160.9 million, representing a 21% increase from $132.5 million in the same period of 2025.
• Net Product Sales: Net product sales were $153.0 million, an increase of 21% from $126.5 million in the prior year period.
• License, Collaboration and Royalty Revenue: License, collaboration, and royalty revenue grew by 36% to $8.0 million, from $5.9 million in the same period of 2025.
• Net Income: Net income was $71.8 million, a 60% increase from $44.9 million in the same period of 2025.
• Income from Operations: Income from operations was $87,763 thousand, compared to $41,930 thousand in the same period of 2025.
• Total Operating Expenses: Total operating expenses were $73,162 thousand, down from $90,543 thousand in the same period of 2025.
  • Cost of revenue: $13,060 thousand, down from $15,689 thousand in 2025.
  • Selling, general and administrative: $45,537 thousand, down from $46,357 thousand in 2025.
  • Research and development: $20,520 thousand, up from $13,175 thousand in 2025.
  • Restructuring: $0, down from $1,647 thousand in 2025.
  • Other (income) expense, net: -$5,955 thousand, compared to $13,675 thousand in 2025.
• Cash Flows from Operating Activities: Cash flows from operating activities were $85.1 million, an 87% increase from $45.5 million in the same period of 2025.
• Cash Flows from Investing Activities: Cash flows from investing activities totaled $63,368 thousand, compared to $17,759 thousand in the same period of 2025.
  • Proceeds from the sale and maturities of investments: $209,000 thousand.
  • Purchases of investments: -$150,805 thousand.
  • Net cash and cash equivalents acquired in acquisition of Kezar: $5,212 thousand.
  • Purchases of property, equipment and intangible assets: -$39 thousand.
• Cash Flows from Financing Activities: Cash flows from financing activities were -$48,875 thousand, compared to -$93,731 thousand in the same period of 2025.
  • Purchase of common shares under Share Repurchase Plan: -$74,880 thousand.
  • Payments of principal portion of Monoplant finance lease liability: -$7,058 thousand.
  • Proceeds from issuance of common shares for equity awards: $59,154 thousand.
  • Proceeds from issuance of common shares under ESPP: $363 thousand.
  • Tax withholding payments related to net settlements of equity awards: -$26,454 thousand.
• Cash Position: As of June 30, 2026, Aurinia Pharmaceuticals Inc. had cash, cash equivalents, restricted cash, and investments totaling $443.1 million, an increase from $398.0 million at December 31, 2025.

Outlook / Guidance

Aurinia Pharmaceuticals Inc. reiterated its 2026 total revenue guidance of $315 million to $325 million, projecting an 11% to 15% increase over 2025. The company also maintained its 2026 net product sales guidance at $305 million to $315 million, anticipating a 12% to 16% increase compared to 2025.